Vi has introduced a new suite of AI agents specifically designed to enhance healthcare, life sciences, and wellness sectors. This strategic move follows the completion of a $145 million funding round, which has raised the company's valuation to $1.64 billion.
The AI agents will serve as an execution layer within Vi's existing platform, integrating with its Activate, Engage, and Operate applications. This innovation aims to identify next-best actions for patients, healthcare teams, and operational processes, ultimately seeking to improve patient care and outcomes.
Vi's platform relies on one of the largest datasets of clinical, behavioral, and operational signals worldwide. This extensive data resource enables the AI agents to make real-time decisions that promise measurable returns on investment in areas such as patient navigation, clinical trial acceleration, and drug commercialization. Vi has already supported over 190 million lives and has helped launch more than 50 drugs into the market, generating over $2 billion in value for its partners.
With an ambitious vision of achieving health abundance globally, Vi aims to ensure that everyone, regardless of socioeconomic status, has access to accurate and affordable healthcare solutions. The recent funding will be directed toward talent acquisition, platform investments, and new product development. Notable contributors to this investment round include General Atlantic, Revelstoke, and The Pritzker Organization, reflecting strong confidence in Vi's growth trajectory.
As healthcare continues to evolve with technological advancements, Vi’s specialized AI agents could significantly reshape the industry. By using data-driven insights, the company seeks to enhance healthcare delivery and operational efficiency, setting a new standard for patient care in the years ahead.
The stories that move AI & crypto markets — before the market reacts.
Free. 7am ET. Five stories. 62,400 readers.
